Financial Information
We introduce ADBIOTECH’s technology intended to replace vaccines
and antibiotics.
Sales
Operating profit
Net profit
Income Statements(Unit: KRW in thousands)
| Item | 2019 | 2020 | 2021 |
|---|---|---|---|
| Sales | 9,343,575 | 9,855,191 | 11,711,552 |
| Cost Of Sales | 4,858,235 | 4,420,793 | 4,927,141 |
| Operating profit | 102,140 | -924,375 | -1,482,585 |
| Non-operating income | 298,735 | 216,651 | 191,117 |
| Non-operating expense | 2,219,731 | 6,696,842 | 1,052,577 |
| Net profit | -1,705,828 | -7,273,246 | -2,593,815 |
Total Assets
Total liabilities
Total equity
Financial Position(Unit: KRW in thousands)
| Item | 2019 | 2020 | 2021 |
|---|---|---|---|
| Current Assets | 5,856,573 | 7,139,444 | 8,678,834 |
| Non-current Assets | 6,058,957 | 11,753,030 | 12,445,478 |
| Total Assets | 11,915,531 | 18,892,474 | 21,124,312 |
| Current liabilities | 12,748,080 | 5,471,936 | 12,654,295 |
| Non-Current liabilities | 70,138 | 4,017,721 | 3,227,821 |
| Total liabilities | 12,818,217 | 9,489,657 | 15,882,117 |
| Share capital | 822,893 | 1,267,337 | 3,846,522 |
| Capital surplus | 2,972,978 | 20,582,470 | 18,292,579 |
| Retained earnings | -6,335,658 | -13,534,319 | -16,128,134 |
| Total equity | -902,687 | 9,402,817 | 5,242,196 |